ALDEYRA THERAPEUTICS INC. overview

Thinking about buying stock in Aldeyra Therapeutics, Alphabet Inc., DraftKings, Evelo Biosciences, or Enlivex Therapeutics? PR Newswire NEW YORK, Nov. 6, 2023 NEW YORK , Nov. 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALDX, GOOGL, DKNG, EVLO, and ENLV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ALDX:...

Thinking about buying stock in Momentus Inc, micromobility.com, Aldeyra Therapeutics, Mullen Automotive, or Processa Pharmaceuticals? PR Newswire NEW YORK, Oct. 20, 2023 NEW YORK , Oct. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MNTS, MCOM, ALDX, MULN, and PCSA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. MNTS:...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of a Class Action against Aldeyra Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ALDX PR Newswire NEW YORK, Sept. 29, 2023 NEW YORK , Sept. 29, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX), and certain officers. The class action, filed in the United States District Court for the District of...

LOS ANGELES, CA / ACCESSWIRE / September 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ:ALDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2022 and June 20, 2023,...

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc.(ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire NEW YORK, Sept. 28, 2023 NEW YORK , Sept. 28, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Aldeyra investors who were adversely affected by alleged...

LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ:ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2022 and June 20, 2023,...

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX) PR Newswire NEW YORK, Sept. 27, 2023 NEW YORK , Sept. 27, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aldeyra Therapeutics, Inc.. Shareholders who purchased shares of ALDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...

ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire LOS ANGELES, Sept. 26, 2023 LOS ANGELES , Sept. 26, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX ). Class Period: March 17, 2022 – June 20, 2023 Lead Plaintiff Deadline: September 29, 2023...